Health

India Proposes Mandatory Quality Audits for Blood Centres, With Penalties for Non‑Compliance

By

India Proposes Mandatory Quality Audits for Blood Centres, With Penalties for Non‑Compliance

New Delhi – A sub‑committee of the Drugs Consultative Committee has drafted proposals that would make participation in external quality assessment schemes (EQAS) legally binding for about 5,000 registered blood centres in India. If the proposals are approved, centres that fail mandatory quality audits could be barred from routine testing until they identify and correct the problems.

The proposals come after several incidents of infected or mismatched blood transfusions in children. In Jharkhand, five children with thalassemia, aged 5 to 7, were reportedly infected with HIV after transfusions at Chaibasa Sadar Hospital.

India collected 14.6 million units of blood in 2024‑25, a 15 % increase year‑on‑year, according to the Union Ministry of Health and Family Welfare. About 70 % of the supply came from voluntary, non‑remunerated donors, underscoring the need for a robust quality management system.

Currently, participation in EQAS is voluntary and there are no legal consequences for lapses in testing or collection processes. In contrast, countries such as the United States, the United Kingdom and members of the European Union require regular proficiency testing for blood banks, linking accreditation and licensing directly to external quality performance. The World Health Organization also recommends compulsory EQAS participation as a core pillar of national haemovigilance and transfusion safety systems.

Under the proposed scheme, blood centres would undergo periodic proficiency testing on a structured January‑to‑December calendar. The Indian Red Cross Society model, which uses three testing cycles per year at a cost of ₹5,000, would serve as a benchmark. Centres would test blind proficiency samples covering blood grouping, cross‑matching, haemoglobin, HIV, hepatitis B, hepatitis C, syphilis and malaria immediately after receipt.

Blind reference samples would be distributed by five apex national EQAS centres – Christian Medical College Vellore, Indian Red Cross Society Mumbai, Santokba Durlabhji Memorial Hospital Jaipur, Post Graduate Institute of Medical Education and Research Chandigarh and Gauhati Medical College Guwahati. State drugs controllers would receive all audit reports to enforce compliance and conduct regulatory reviews.

If a centre fails to meet proficiency standards during a cycle, it would be prohibited from continuing routine testing without review. The centre would be required to conduct a formal root‑cause analysis (RCA) and implement a corrective and preventive action (CAPA) protocol. Proposed penalties for non‑compliance include statutory fines, suspension of testing privileges and disciplinary action by state regulators.

The proposals were drafted by a five‑member sub‑committee chaired by Rajasthan drugs controller Ajay Phatak and included state drugs controllers from Jharkhand and Punjab, representatives from the National Blood Transfusion Council and the CDSCO blood centre division.

The Drugs Consultative Committee, a top statutory advisory panel of central and state drug regulators, will soon make a final decision. Before notifying any amendments, the National Blood Transfusion Council will develop a phased transition plan, operational guidelines, sample pricing norms and non‑compliance criteria to avoid disruptions to the blood supply. Draft rules will be sent to state blood transfusion councils for feedback.

Experts say mandatory external quality assessments are essential to identify testing inaccuracies before they compromise patient safety. "Blood centres must maintain validated testing procedures, trained personnel, proper documentation and continuous monitoring. Any failure should trigger immediate investigation and corrective action," said Vijay Kumar Sharma, consultant in internal medicine at Regency Healthcare.

"Blood transfusion accounts for the major source of viral transmission. Untested or semi‑tested blood transfusion is still common, especially in peripheries. This move can help, although it cannot fully ensure that the centres follow the SOPs and guidelines," added Ravneet Kaur, general manager and lab head at Agilus Diagnostics Lab, Fortis Noida.

Frequently asked questions

How many blood centres will be affected by the new mandatory EQAS?

About 5,000 registered blood centres in India.

What penalties could a blood centre face if it fails an EQAS audit?

The centre could be barred from routine testing, face statutory fines, suspension of testing privileges, and disciplinary action by state regulators.

What prompted India to propose mandatory EQAS for blood centres?

Several incidents of infected or mismatched blood transfusions, including five children in Jharkhand who were infected with HIV after transfusions at Chaibasa Sadar Hospital.

Related stories